In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah® (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The most recent results from the trial will be presented today at the 60th American… Read More »
SAN DIEGO (Reuters) – Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc’s Yescarta continued to respond to the cell therapy after at least two years of follow up, the company said on Sunday. FILE PHOTO: A Gilead Sciences, Inc. office is shown in Foster City, California, U.S. May… Read More »
ZURICH (Reuters) – Novartis’s price-setting muscle is about to be tested after it won European Union approval for a blindness-fighting gene therapy whose $ 850,000 list cost in the United States has been labeled too expensive by some groups. FILE PHOTO: A Novartis logo is pictured on its headquarters building in Mumbai April 1, 2013.… Read More »
Create an RSS feed from your search for: Recruiting, Not yet recruiting, Available Studies | “physical therapy” Need help? See RSS Feeds Choose a feed type: Show studies that were first added (first posted) in the last 14 days Show studies added or modified (last update posted) in the last 14 days Cancel New Links… Read More »